News | Published:

Living therapeutics: Scientists genetically modify bacteria to deliver drugs

Nature Medicine volume 23, pages 57 (2017) | Download Citation

  • A Correction to this article was published on 07 March 2017

This article has been updated

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Change history

  • 15 February 2017

    In the January 2017 issue, the piece “Living therapeutics: Scientists genetically modify bacteria to deliver drugs” (Nat. Med. 23, 5–7, 2017) incorrectly stated that the company Oragenics is slated to launch a phase 2 trial on ulcerative mucositis next year. In fact, they will begin the trial in 2017. The error has been corrected in the HTML and PDF versions of this article.

References

  1. 1.

    Joint United Nations Programme on HIV/AIDS. 2004 report on the global AIDS epidemic. (4th global report) 1–236 (UNAIDS, Geneva, 2004).

  2. 2.

    Antonie Van Leeuwenhoek 82, 323–331 (2002).

  3. 3.

    et al. Nat. Biotechnol. 21, 785–789 (2003).

  4. 4.

    et al. Mucosal Immunol. 3, 49–56 (2010).

  5. 5.

    et al. Cancer 119, 4268–4276 (2013).

  6. 6.

    et al. Mucosal Immunol. 4, 648–657 (2011).

  7. 7.

    et al. Sci. Transl. Med. 6, 249ra111 (2014).

  8. 8.

    , , & Biotechnol. Bioeng. 113, 2698–2711 (2016).

  9. 9.

    , & et al. Nat. Rev. Microbiol. 4, 193–200 (2006).

Download references

Author information

Affiliations

  1. Amy Maxmen is a freelance science journalist based in Berkeley, California.

    • Amy Maxmen

Authors

  1. Search for Amy Maxmen in:

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nm0117-5

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing